An increasing risk of death after hip fracture has been well documented, but the duration and causes remain unclear, especially in very frail older people. This is a nested case-control study of 229 hip fracture cases and 229 controls matched by age, gender, institution type, and follow-up period from a cohort of 2005 institutionalized older people. The residents were assessed at baseline and followed up for hip fracture and death for at least 5 years. Time to death was measured from the same time for each case (time of the hip fracture) and the matched control. The study sample consisted of 90 males and 368 females with a mean age of 86 years (range 67 to 102 years). The hazard ratio (HR) of death for the cases compared with the controls was 3.09 [95% confidence interval (CI) 1.83-5.22, p < .001] for the first 3 months, 1.99 (95% CI 1.13-3.51, p ¼ .02) for the period of 3 to 9 months, and 0.88 (95% CI 0.64-1.22, p ¼ .46) for the period beyond 9 months following a fracture, after adjusting for age, gender, institution type, weight, immobility, cognitive function, comorbidities, and number of medications. The main causes of the excess mortality in the first 9 months were infections (HR ¼ 6.66, 95% CI 1.95-22.77, p ¼ .002) for females and cardiac disease (HR ¼ 2.68, 95% CI 1.39-5.15, p ¼ .003) for both males and females. Bisphosphonate use was associated with a reduction in mortality after hip fracture ( p ¼ .002). Intensive medical supervision to reduce cardiovascular and infective complications should be provided for frail older people with recent hip fracture to reduce mortality. ß
Introduction
A n increasing risk of death after hip fracture has been well recognized. About 1 in 5 persons who sustain a hip fracture will die within 1 year of the fracture. (1, 2) This excess of deaths compared with that expected in an age-matched population has been attributed to increased numbers of comorbidities. Recently, it was reported that intravenous bisphosphonate therapy could decrease the risk of death 16 months after a hip fracture but not before, (3) with subsequent analyses suggesting that most of the deaths so prevented were cardiovascular or infectious in nature. (4) Why mortality was not reduced earlier than 16 months remains unclear, as do the actual mechanisms of any such reduction.
Little is known about the specific causes of death that contribute to the excess deaths after hip fracture, and the duration of the increasing mortality attributable to hip fracture varies significantly among studies, ranging from less than 6 months up to 10 years. (5, 6) The magnitude also varies, with the rate of excess death after hip fracture appearing to be much higher among institutionalized older people. (7) One explanation their fractures. Hence an increased risk of death in the first few months following hip fracture might be expected in this group, but this increased risk might not last for a long period of time. On the other hand, a hip fracture might not result in immediate death for patients who are relatively healthier and younger but subsequently could induce a progressive decline in functional outcomes and the patients' health. As a result, an increasing mortality might not occur until 1 to 2 years after the fracture but might last for a prolonged period. Thus different durations of the increasing risk of death observed in these previous studies could be explained at least in part by differences in population compositions of study subjects between the studies. Moreover, many studies have compared death rate of their hip fracture patients with the age-and sex-adjusted rate of the general population, resulting in an overestimated risk of death owing to hip fracture. Hip fractures occur more often in persons who have a greater number of medical and functional deficits and therefore higher chances of dying even without the fracture. In this study we examined prospectively a subset of a cohort of frail older people with and without a hip fracture who were living in nursing homes and intermediate-care facilities in Australia. The aims were to (1) determine the magnitude of the increasing risk of death after hip fracture among institutionalized older people and (2) identify the long-term temporal pattern and causes of death that are associated with the excess mortality.
Patients and Methods

Subjects
In this nested case-control study, we compared all 229 hip fracture cases with 229 controls matched by age (within 5 years), gender, institution type, and follow-up period. The participants were from a prospective cohort ( (8, 9) Individuals who were bed bound, bilateral amputees, or non-English speaking or under the age of 65 years were excluded from the FREE Study. All residents gave informed consent, or if unable, their next of kin gave proxy consent. Ethics approval was given by the local health service human research ethics committee.
Baseline and outcomes assessments
The residents were assessed with reference to age, sex, type of residential care facility (nursing home and intermediate-care hostel), immobility (if needed to assistance to transfer), comorbidities [assessed using a modification of the Implicit Illness Severity Rating Scale (IISC)], (10) cognitive functioning [by Standardized Mini
Mental State Examination (SMMSE)], (11) and medication use in the last month. Bone fragility was assessed by quantitative ultrasound (QUS), and broadband ultrasound attenuation (BUA, a QUS parameter) was measured in the calcaneus using a McCue Cuba Mark II machine (McCue Ultrasonics, London, UK). Biochemical markers of bone turnover were measured in about half the subjects, as reported previously. (12) Briefly, serum concentrations of the intact amino-terminal propeptide of type I procollagen (PINP), a marker of bone formation, and of the carboxy-terminal telopeptide of type I collagen (CTX-I), a marker of bone resorption, were determined using automated immunoassays (Elecsys 170, Roche Diagnostics GmbH, Germany The methods of analysis were Kaplan-Meier survival curves and piecewise Cox regression analyses. The Kaplan-Meier method provides a graphic comparison, whereas Cox proportional hazards regression allows a comparison of mortality between those with and without hip fracture while adjusting for other variables. Because the proportional hazards assumption did not hold over the whole time period (5 years), it was split at 3 and 9 months to give more homogeneous time periods, in which the assumption did hold (and hence the hazard ratio could be estimated validly). For specific causes of death, Cox proportional hazards regression was used to estimate average risk of death during the first 9 months because the proportional hazards assumption held for each cause of death in this time period. Effect modification for gender was tested by including interaction terms with gender.
Results
The study sample consisted of 90 males and 368 females with a mean age of 86 years (range 67 to 102 years) at baseline. There were 115 fractures of the trochanteric region, 113 of the femoral neck, and 1 involving both sites. The average time to hip fracture was 2.26 (SD 1.82) years. After matching for age, gender, and type of institution, people with hip fractures were likely to be more mobile, thinner, on antiosteoporotic medications (i.e., bisphosphonate, hormone-replacement therapy, vitamin D, or calcium) and had better scores on Implicit Illness Severity Rating Scale (Table 1) . While there was no significant difference between serum 25(OH)D and PTH between the cases and controls, cases had higher baseline bone markers, both serum PINP and CTX-I.
Temporal pattern of death
Among the cases, death rates at 3, 6, 9, and 12 months were 26%, 35%, 41%, and 45%, respectively. The corresponding death rates for the controls were 9%, 16%, 19%, and 25%, respectively. The Kaplan-Meier survival curves for the cases and controls show that the greatest excess mortality occurred in the first 3 months after the hip fracture. This excess risk had disappeared by about 9 months after the hip fracture (Fig. 1) . The findings are supported by piecewise Cox regression analysis of the data. The hazard ratio (HR, similar to a relative risk) of death for the cases compared with controls was 3.34 [95% confidence interval (CI) 2.01-5.55, p < .001] for the first 3 months, 1.87 (95% CI 1.11-3.13, p ¼ .02) for the period of 3 to 9 months, and 1.00 (95% CI 66 (14) 40 (18) 26 (11) .06
Any antiosteoporotic medications, n (%) 83 (18) 50 (22) 33 (14) .04 Immobility, n (%) 31 (7) 7 (3) 24 (11 Matching variables (significance not tested). Table 2 ). Baseline levels of serum 25(OH)D did not affect the relationship between hip fracture and death.
Causes of death in the first 9 months
The primary causes of death in participants with and without hip fracture in the period of 0 to less than 3, 3 to 9, or more than 9 months following a fracture are shown in Table 3 . The composition of four specific causes of deaths, namely, cardiac, cerebrovascular, infections, and others, was the same in the first 3 months as in the period of 3 to 9 months ( p ¼ .93) among residents with a hip fracture. There were 95 deaths in the hip fracture group and 44 in the control group in the first 9 months. With regard to the risk of death in the first 9 months, for death owing to cardiac causes the adjusted HR was 2.68 (95% CI 1. Table 3 also shows the number of deaths owing to subcategories such as pneumonia and arrhythmia for the cases and controls. In some of these deaths, pneumonia and arrhythmia deaths were not classified as the primary cause on the death certificate but rather as a secondary cause. The adjusted HR was 3.57 (95% CI 1.53-8.33, p ¼ .003) for pneumonia and 3.32 (95% CI 0.89-12.42, p ¼ .08) for arrhythmia. These analyses were adjusted for age, gender, institution type, weight, immobility, cognitive function, comorbidities, and number of medications. Between 9 months and 5 years, there appeared to be a somewhat decreased number of deaths in the hip fracture group owing to cardiac, stroke, and infective causes (see Table 3 ), but this may reflect the prior higher mortality owing to these causes in the first 9 months (with accordingly fewer survivors beyond 9 months) because the overall risk of death was not increased after adjustment for comorbidities ( 
Discussion
This study found that the risk of death was increased for 9 months after a hip fracture, with subjects who sustained a hip fracture having more than double the chance of dying during that period. The population studied was at high risk of hip fracture and death, being very elderly and institutionalised. Cardiac and infective causes were the two major contributors to the excess death rate. Pneumonia appeared to be the cause that contributed most to the deaths owing to infection. With regard to cardiac deaths, it was not possible to subdivide deaths into those truly owing to intrinsic cardiac disease versus those which occurred because of pulmonary embolism, but arrhythmias were commonly recorded as contributing to death in hip fracture cases.
The duration of increased mortality attributable to hip fracture varies considerably in previous studies. (1, 2, 6, (13) (14) (15) (16) (17) (18) (19) (20) In a study of 709 patients consecutively admitted to two hospitals in the United Kingdom with hip fracture, Parker and colleagues (17) reported that 37% had died by 12 months.
They estimated the excess mortality owing to hip fracture as 15%, after accounting for conditions owing to aging. Lu-Yao and colleagues (14) reported that the 30-day mortality after hip fracture was 11% for men and 6% for women, whereas the overall mortality at 12 months was 24%. Mortality was increased in those residing in nursing homes or who had significant comorbid conditions. Luthje and colleagues (15) reported that excess mortality in a Finnish study was 21% in men and 16% in women after 1 year, wheres at 4 years mortality was 37% for men and 24% for women. Patients who sustained fractures in an institution had a higher excess mortality than those in the community. Magaziner and colleagues (2) reported that the proportion of deaths within 12 months following fracture was 17.4%. In patients aged 85 years of age or older, the mortality rate approached that expected by approximately 6 months after hip fracture. In the EPIDOS study, (13) increased mortality was greatest for the first 6 months after hip fracture but persisted for 3 years. Wehren and colleagues (20) related the increased mortality in men compared with women as being due to infections even 2 years after fracture. Of interest, Magaziner and colleagues (16) reported that for patients with three or more functional impairments or one or more comorbidities, the excess mortality had disappeared by 4 years. Using data derived from a large administrative data set in Germany of older people living in nursing homes, Rapp and colleagues (18) reported that mortality was increased (women: HR for the first 3 months after hip fracture 1.72, 95% CI 1.59-1.86; men: HR 2.14, 95% CI 1.80-2.53), but there was limited information on the causes of death after hip fracture. Lyles and colleagues (3) reported a 28% reduction in risk of death in patients treated with zoledronic acid compared with placebo following a hip fracture. However, the beneficial effect of zoledronic acid on mortality was not seen until 16 months, when the curves separated. A subsequent analysis of data from this trial suggested that only a small proportion of the reduction in mortality was due to prevention of further fractures and that most of the deaths prevented beyond 16 months were cardiovascular and infective in nature. (4) We also observed a reduction in mortality over the first 3 years after hip fracture in bisphosphonate users. Bisphosphonates have a number of effects on nonbone targets that may be relevant to infection-related deaths. For example, they can activate gd T cells, which contribute to immune defense against infection (21) and affect interferon g (IFN-g) and tumor necrosis factor a (TNF-a) levels, (22) and these immune effects may translate into effects on susceptibility to infection. Zoledronic acid is associated with a higher risk of concomitant acute-phase reactions than other bisphosphonates, which theoretically may enhance an elderly person's underlying immune system status. (23) However, it seems difficult to reconcile why zoledronic acid would reduce cardiovascular and infection-related mortality beyond 16 months after hip fracture but have no effect on acute mortality in the first 9 months, when the majority of deaths in that period reflect excess deaths owing to cardiac and infective causes, according to our study. Indeed, in our study, deaths owing to cardiac, stroke, and infective causes were somewhat decreased between 9 months and 5 years after hip fracture, presumably in part related to the higher mortality in the early period. This study has certain strengths and limitations. We used a large cohort with data collected prospectively and observed a large number of hip fractures over a long period of follow-up. We also were able to match hip fracture subjects with appropriate frail elderly controls. By using death certificates, we had complete data on mortality in the whole cohort.
However, we only collected data about risk factors at baseline. Because biochemical markers of bone turnover were measured in only about half the participants, we could not use these data in the survival analyses. We used the primary cause of death on the death certificate for analytical purposes, as well as extracting secondary causes. Cause of death on the death certificate represent a medical opinion that might vary among individual physicians, but we attempted to verify these by patient chart review. Inaccuracies in death certification are well recognized but most likely would have affected our hip fracture and control group equally. The cause-of-death section on death certificates in New South Wales (Australia) consists of two parts. The first part is for the immediate cause of death, which we used as the primary cause of death in our analyses, whereas the second part includes significant diseases that contributed to death but which did not result in the underlying cause of death specified in the first part. We used the second part to examine secondary causes of death that may be of interest, but this represents an exploratory analysis only. The significance of the gender interaction showing higher infective deaths in women could be due to chance because in models related to death from all causes or other specific causes, no interactions between gender and hip fracture were observed. Similarly, the effect of bisphosphonates in reducing mortality was observed in a relatively small number of patients (n ¼ 17; 13 were taking alendronate, 4 were taking etidronate).
Our findings indicate that in frail older people with hip fracture, risk of death is increased in the first 9 months, mainly from cardiovascular and infective causes. These findings have potentially important clinical implications. For example, in the early phase following hospital discharge, regular and coordinated health care (including medical, nursing, and allied health components) should mitigate some of the risks that we have demonstrated. Specific examples of potential changes in current practice that may reduce cardiovascular and infective mortality include (1) the need to continue thromboprophylaxis after discharge for institutionalized older people with hip fracture, (2) removal of urinary catheters as a priority as soon as feasible following hip fracture (and certainly before discharge from hospital), (3) encouragement of influenza and pneumococcal disease immunization, and (4) nutritional support for undernourished patients given the potential link between nutrition and immune system functioning. Increased attention to other aspects of treatment after hip fracture, such as treatment of anaemia and vitamin D deficiency and reestablishment of mobility and reduction in falls risk, also should have higher priority. However, reduced physiologic reserve in these subjects owing to their frailty may mean that some of this increased mortality risk is unavoidable. Based on our results, the mechanism of the effect of hip fracture on mortality from cardiovascular and infective causes and how it may be reduced require further investigation.
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